Curative effect of carvedilol in the elderly with portal hypertension of hepatitis b cirrhosis

doi:10.3877/cma.j.issn.2095-8757.2018.04.007

Abstract

Abstract:

Objective

To evaluate carvedilol in elderly patients with hepatitis b cirrhosis portal hypertension levy of therapeutic effect.

Methods

60 elderly patients with portal hypertension of hepatitis b liver cirrhosis were randomly divided into treatment group and control group using random number table method from August 2014 to January 2018 in Tai'an central hospital, which included 30 cases in each group. The control group underwent routine hepatoprotective, antiviral and anti fibrosis treatment. The treatment group underwent oral carvedilol treatment on the basis of conventional treatment. Six months after oral carvedilol, portal venous blood flow dynamics, the degree of esophageal gastric varices, liver fibrosis index and blood coagulation index changes were observed. In the portal venous hemodynamics, liver fibrosis index and blood coagulation index changes, the control group and treatment group were using two independent sample t test. In the aspect of the change of the degree of esophageal gastric varices, control group and treatment group were using rank sum test and Mann-Whitney U test.

Results

Before taking carvedilol, there were no statistically significant difference in portal venous blood flow dynamics, the degree of esophageal gastric varices, liver fibrosis index and blood coagulation index between control group and treatment group (P>0.05). After taking carvedilol, the above four aspects of the treatment effect were significantly improved (P<0.05).

Conclusion

On the basis of conventional treatment, oral carvedilol treatment can significantly improve the therapeutic effect of elderly patients with hepatitis b cirrhosis portal hypertension.

Key words: Carvedilol, Liver cirrhosis portal hypertension, Treatment effect, Aged

Cuifang Nie, Shengqiang Yang, Xianghua Ye. Curative effect of carvedilol in the elderly with portal hypertension of hepatitis b cirrhosis[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2018, 05(04): 29-33.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlnbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8757.2018.04.007

https://zhlnbyjdzzz.cma-cmc.com.cn/EN/Y2018/V05/I04/29

Figures/Tables 4

References 22

[1]	庄辉.乙型肝炎流行病学研究进展[J].国外医学流行病学传染病学分册，2004，31(3):133-135.
[2]	刘南值，尹朝礼.790例门脉高压食管胃底静脉曲张内镜检查分析[J].内科急危重症杂志，2010，7(1):22-23.
[3]	刘天舒，王吉耀.现代肝病治疗理论与进展[M].上海：上海医科大学出版社，2009：188-198.
[4]	Tripathi D, Hayes PC.Beta-blockers in portal hypertension: new devel-opments and controversies[J]. Liver Int, 2014, 34(5):655-667.
[5]	Bosch J. Carvedilol for portal hypertension in patients with cirrhosis[J]. Hepatology, 2010, 51(6):2214-2218.
[6]	中华医学会传染病与寄生虫病学分会、肝病学分会联合修订.病毒性肝炎防治方案[J].中华肝脏病杂志，2000，8(6):324-329.
[7]	钱蕴秋.实用超声诊断手册[M].北京：人民军医出版社，1998：378.
[8]	中华消化内镜学会.食管胃底静脉曲张内镜下诊断和治疗规范试行方案[C].第六届国际治疗内镜和消化疾病学术会议汇编2001：35-39.
[9]	李国军，洪捷敏，邹何慧，等.肝硬化住院患者合并医院感染的临床特征[J].中华医院感染学杂志，2011，21(4):685-686.
[10]	Sola R, Alvarez MA, Balleste B, et al. Probability of liver cancer and survival in HCV-related or alcoholic-decompensated cirrhosis. A study of 377 patients[J]. Liver Int, 2006, 26(1):62-72.
[11]	张薇薇，袁学华，朱琳，等.176例失代偿期肝硬化预后影响因素的回顾分析[J].临床肝胆病杂志，2009，25(5):377-379.
[12]	Bosch J, Berzigotti A, Garcia-Pagan JC, et al. The management of portal hypertension: rational basis, available treatments and future options[J]. Hepatology, 2008, 48(Suppl 1):S68-S92.
[13]	Amico DG, Luca A. Natural history. Clinical-haemodynamic correl-ations. Prediction of the risk of bleeding[J]. Baillieres Clin Gas-troenterol, 1997, 11(2):243-256.
[14]	Benoit JN, Womack WA, Hernandez L, et al. "Forward" and "backward" flow mechanisms of portal hypertension. Relative contributions in the rat model of portal vein stenosis[J]. Gastroenterology, 1985, 89(5):1092-1096.
[15]	Ryan BM, Stockbrugger RW, Ryan JM. A pathophysiologic, gastroe-nterologic, and radiologic approach to the management of gastric va-rices[J]. Gastroenterology, 2004, 126(4):1175-1189.
[16]	Bosch J. Carvedilol for portal hypertension in patients with cirr-hosis[J]. Hepatology, 2010, 51(6):2214-2218.
[17]	Hem street BA. Evaluation of carvedilol for the treatment of portal hypertation[J]. Pharm acotherapy, 2004, 24(1):94-104.
[18]	Tripathi D, Hayes PC. Beta-lockers in potal hypertention: new developments and controversises[J]. Liver Int, 2014, 34:655-667.
[19]	Huang H, Shan J, Pan XH, et al. Carvedilol protected diabetic rathearts via reducing oxidative stress[J]. Zhejiang Univer SciB, 2006, 7(9):725-731.
[20]	Pietrangeio A. Iron oxidative stress and liver fibrosis[J]. Hepatology, 1998, 28(suppl 1):8-13.
[21]	Jiao J, Friedman SL, Aloman C. Hepatic fibrosis[J]. Curr Opin Gastroenterol, 2009, 25(3):223-229.
[22]	Newby DE, Hayes PC. Hyperdynamic circulation in liver cirrhosis: not peripheral vasodilatation but "splanchanic steal" [J]. QJM, 2002, 95(12):827-830.

组别	例数	DPV(mm)				DSV(mm)
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
观察组	30	15.21±1.98	12.74±3.15	3.636	<0.01	12.52±1.76	10.05±2.45	4.4727	<0.01
对照组	30	14.96±1.58	14.87±1.67	0.214	>0.05	12.71±2.23	11.98±1.25	1.5640	>0.05
t值	?	0.541	3.272	?	?	0.366	3.843	?	?
P值	?	>0.05	<0.01	?	?	>0.05	<0.01	?	?
组别	例数	QPV(ml/s)				QSV(ml/s)
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
观察组	30	15.57±5.61	12.47±4.68	2.324	<0.05	13.27±5.99	9.61±6.42	2.2831	<0.05
对照组	30	15.91±5.58	15.72±5.62	0.131	>0.05	13.12±6.1	12.98±5.97	0.0896	>0.05
t值	?	0.235	2.434	?	?	0.096	2.106	?	?
P值	?	>0.05	<0.01	?	?	>0.05	<0.05	?	?

组别	例数	DPV(mm)				DSV(mm)
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
观察组	30	15.21±1.98	12.74±3.15	3.636	<0.01	12.52±1.76	10.05±2.45	4.4727	<0.01
对照组	30	14.96±1.58	14.87±1.67	0.214	>0.05	12.71±2.23	11.98±1.25	1.5640	>0.05
t值	?	0.541	3.272	?	?	0.366	3.843	?	?
P值	?	>0.05	<0.01	?	?	>0.05	<0.01	?	?
组别	例数	QPV(ml/s)				QSV(ml/s)
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
观察组	30	15.57±5.61	12.47±4.68	2.324	<0.05	13.27±5.99	9.61±6.42	2.2831	<0.05
对照组	30	15.91±5.58	15.72±5.62	0.131	>0.05	13.12±6.1	12.98±5.97	0.0896	>0.05
t值	?	0.235	2.434	?	?	0.096	2.106	?	?
P值	?	>0.05	<0.01	?	?	>0.05	<0.05	?	?

组别	例数	轻度		中度		重度
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	30	9(30.0)	13(43.3)	14(46.7)	13(43.3)	7(23.3)	4(13.4)
对照组	30	10(33.3)	9(30.0)	14(46.7)	15(50.0)	6(20.0)	6(20.0)

组别	例数	轻度		中度		重度
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	30	9(30.0)	13(43.3)	14(46.7)	13(43.3)	7(23.3)	4(13.4)
对照组	30	10(33.3)	9(30.0)	14(46.7)	15(50.0)	6(20.0)	6(20.0)

组别	例数	HA（ng/ml）				PCⅢ（ng/ml）
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
观察组	30	149.15±57.24	103.21±52.17	3.249	<0.01	101.21±42.20	79.98±34.72	2.128	<0.05
对照组	30	158.14±62.47	155.42±60.13	0.172	>0.05	98.43±40.76	99.57±35.38	0.116	>0.05
t值	?	0.581	3.592	?	?	0.260	2.165	?	?
P值	?	>0.05	<0.01	?	?	>0.05	<0.05	?	?
组别	例数	LN（ng/ml）				CⅣ（ng/ml）
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
观察组	30	112.54±37.28	96.87±32.54	1.735	<0.05	89.68±41.59	70.56±24.65	2.166	<0.05
对照组	30	117.61±39.67	112.14±36.79	0.554	>0.05	91.35±29.62	90.13±28.71	0.162	>0.05
t值	?	0.510	1.703	?	?	0.179	2.833	?	?
P值	?	>0.05	<0.05	?	?	>0.05	<0.01	?	?

Please choose a citation manager

Content to export